Literature DB >> 736651

A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods.

C M Balch, T M Murad, S J Soong, A L Ingalls, N B Halpern, W A Maddox.   

Abstract

A multifactorial analysis was used to identify the dominant prognostic variables affecting survival from a computerized data base of 339 melanoma patients treated at this institution during the past 17 years. Five of the 13 parameters examined simultaneously were found to independently influence five year survival rates: 1) pathological stage (I vs II, p = 0.0014), 2) lesion ulceration (present vs absent, p = 0.006), 3) surgical treatment (wide excision vs wide excision plus lymphadenectomy, p = 0.024), 4) melanoma thickness (p = 0.032), and 5) location (upper extremity vs lower extremity vs trunk vs head and neck, p = 0.038). Additional factors considered that had either indirect or no influence on survival rates were clinical stage of disease, age, sex, level of invasion, pigmentation, lymphocyte infiltration, growth pattern, and regression. Most of these latter variables derived their prognostic value from correlation with melanoma thickness, except sex which correlated with location (extremity lesions were more frequent on females, trunk lesions on males). This statistical analysis enabled us to derive a mathematical equation for predicting an individual patient's probability of five year survival. Three categories of risk were delineated by measuring tumor thickness (Breslow microstaging) in Stage I patients: 1) thin melanomas (<0.76 mm) were associated with localized disease and a 100% cure rate: 2) intermediate thickness melanomas (0.76-4.00 mm) had an increasing risk (up to 80%) of harboring regional and/or distant metastases and 3) thick melanomas (>/=4.00 mm) had a 80% risk of occult distant metastases at the time of initial presentation. The level of invasion (Clark's microstaging) correlated with survival, but was less predictive than measuring tumor thickness. Within each of Clark's Level II, III and IV groups, there were gradations of thickness with statistically different survival rates. Both microstaging methods (Breslow and Clark) were less predictive factors in patients with lymph node or distant metastases. Clinical trials evaluating alternative surgical treatments or adjunctive therapy modalities for melanoma patients should incorporate these parameters into their assessment, especially in Stage I (localized) disease where tumor thickness and the anatomical site of the primary melanoma are dominant prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 736651      PMCID: PMC1397001          DOI: 10.1097/00000658-197812000-00004

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  STAGING OF MALIGNANT MELANOMAS BY DEPTH OF INVASION; A PROPOSED INDEX TO PROGNOSIS.

Authors:  J H MEHNERT; J L HEARD
Journal:  Am J Surg       Date:  1965-08       Impact factor: 2.565

3.  Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults.

Authors:  N LANE; R LATTES; J MALM
Journal:  Cancer       Date:  1958 Sep-Oct       Impact factor: 6.860

4.  Malignant melanoma; clinical and pathologic analysis of 93 cases. Is prophylactic lymph node dissection indicated?

Authors:  R H LUND; M IHNEN
Journal:  Surgery       Date:  1955-10       Impact factor: 3.982

5.  Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis.

Authors:  A C ALLEN; S SPITZ
Journal:  Cancer       Date:  1953-01       Impact factor: 6.860

6.  Malignant melanomas of the skin. A study of the origin, development, aetiology, spread, treatment, and prognosis. I.

Authors:  N C PETERSEN; D C BODENHAM; O C LLOYD
Journal:  Br J Plast Surg       Date:  1962-01

7.  A rational approach to the surgical management of melanoma.

Authors:  E C Holmes; H S Moseley; D L Morton; W Clark; D Robinson; M M Urist
Journal:  Ann Surg       Date:  1977-10       Impact factor: 12.969

8.  A clinicopathologic study of prognostic factors in cutaneous malignant melanoma.

Authors:  E G Elias; M S Didolkar; I P Goel; J F Formeister; L A Valenzuela; J L Pickren; R H Moore
Journal:  Surg Gynecol Obstet       Date:  1977-03

9.  Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.

Authors:  M H Cohen; A S Ketcham; E L Felix; S H Li; M M Tomaszewski; J Costa; A S Rabson; R M Simon; S A Rosenberg
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

10.  A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results.

Authors:  F H Sim; W F Taylor; J C Ivins; D J Pritchard; E H Soule
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

View more
  69 in total

1.  Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up.

Authors:  Torsten Hinz; Hojjat Ahmadzadehfar; Anja Wierzbicki; Tobias Höller; Jörg Wenzel; Hans-Jürgen Biersack; Thomas Bieber; Monika-H Schmid-Wendtner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-08       Impact factor: 9.236

2.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

Review 4.  Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Authors:  Sabran J Masoud; Jennifer A Perone; Norma E Farrow; Paul J Mosca; Douglas S Tyler; Georgia M Beasley
Journal:  Curr Treat Options Oncol       Date:  2018-09-19

5.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

6.  Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat.

Authors:  C L Day; T J Harrist; F Gorstein; A J Sober; R A Lew; R J Friedman; B S Pasternack; A W Kopf; T B Fitzpatrick; M C Mihm
Journal:  Ann Surg       Date:  1981-07       Impact factor: 12.969

7.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator.

Authors:  J W Kelly; R W Sagebiel; S Clyman; M S Blois
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

9.  The extent of primary melanoma excision. A re-evaluation--how wide is wide?

Authors:  D R Aitken; K Clausen; J P Klein; A G James
Journal:  Ann Surg       Date:  1983-11       Impact factor: 12.969

10.  Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology.

Authors:  Ozge Gumusay; Ugur Coskun; Tülay Akman; Ahmet Siyar Ekinci; Muharrem Kocar; Ozlem Balvan Erceleb; Ozan Yazıcı; Mehmet Ali Kaplan; Veli Berk; Bulent Cetin; Burcu Yapar Taskoylu; Ayhan Yildiz; Gamze Goksel; Ahmet Alacacioglu; Umut Demirci; Efnan Algin; Mukremin Uysal; Ilhan Oztop; Berna Oksuzoglu; Faysal Dane; Mahmut Gumus; Suleyman Buyukberber
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-29       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.